Home / Market News / $ARDX
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Ardelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial for IBSRELA in Chronic Idiopathic Constipation

Nov 3, 2026, 10:36 PM UTC · Primary ticker $ARDX

Ardelyx has completed enrollment for its Phase 3 ACCEL clinical trial for IBSRELA in chronic idiopathic constipation (CIC) ahead of schedule. This development is a positive step towards potentially expanding the drug's approved indications, but topline data is not expected until the second half of 2027, limiting immediate market impact.

Ardelyx announced the completion of enrollment for its Phase 3 ACCEL clinical trial for IBSRELA in chronic idiopathic constipation (CIC), ahead of schedule. This is a positive operational milestone, indicating the trial is progressing efficiently. The significance lies in the potential expansion of IBSRELA's market, as it is currently only approved for IBS-C. If successful, this could significantly increase Ardelyx's revenue streams in the long term. However, the market impact is somewhat muted in the short term as topline data is not expected until the second half of 2027, meaning investors will have to wait for definitive results. For traders, this represents a long-term opportunity if the trial is successful, but there's no immediate catalyst for a significant price movement.

$ARDX positive Advancement of key clinical trial
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.